However, the prognosis of FASN expression in anti-PD-1 immunotherapy and anti-PD-L1 treatment methods is diametrically opposite, which may be due to the different functions of FASN in tumor cells and tumor-associated T cells. This evidence concerns the gene FASN and neoplasm.